title: Autoantibodies against insulin-like growth factor‑binding protein-2             as a serological biomarker in the diagnosis of lung cancer.
abstract: Insulin-like growth factor-binding protein-2 (IGFBP-2) is considered to be a human tumor antigen, and the tumor-specific immunity of IGFBP-2 has been reported in several types of cancer. The purpose of this study was to evaluate whether autoantibodies to IGFBP-2 can be used as diagnostic markers in lung cancer. The results demonstrated that serum anti-IGFBP-2 autoantibody levels were significantly elevated in lung cancer (mean, 1,633.318 ng/ml; median, 1,651.462 ng/ml; range, 342.732-4932.582 ng/ml) compared with benign lung disease (1,210.139, 1,035.900, 547.596‑2,331.167 ng/ml) and normal controls (1,303.369, 1,194.800, 528.200-2140.500 ng/ml). The sensitivity and speciﬁcity of anti-IGFBP-2 autoantibodies in diagnosing lung cancer was 73.2 and 60.6%, respectively. When serum IGFBP-2 and anti-IGFBP-2 autoantibody were used together in the diagnosis of lung cancer, it can increase the discriminative power for lung cancer with a sensitivity of 85.7% and a specificity of 57.5%. In conclusion, this study demonstrates that circulating anti-IGFBP-2 autoantibodies can be used as a potential biomarker in diagnosing lung cancer.
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Xi'an Jiao Tong University Medical Center, Shaanxi, People's Republic of China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhang
authors.forename: Xia
authors.initials: X
authors.lastname: Ying
authors.forename: Suxia
authors.initials: S
authors.lastname: Han
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.forename: Xia
authors.initials: X
authors.lastname: Zhou
authors.forename: E
authors.initials: E
authors.lastname: Bai
authors.forename: Jianying
authors.initials: J
authors.lastname: Zhang
authors.forename: Qing
authors.initials: Q
authors.lastname: Zhu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000097:blood*; D015415:Biomarkers / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D018971:Insulin-Like Growth Factor Binding Protein 2 / Q000097:blood* / Q000276:immunology*; D008175:Lung Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D012372:ROC Curve
chemical_list: D001323:Autoantibodies; D015415:Biomarkers; D014408:Biomarkers, Tumor; D018971:Insulin-Like Growth Factor Binding Protein 2